Predictors of Impaired Survival in Subjects With Long-Term Oxygen Therapy

References

1. 1.↵
   Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980;93(3):391–398.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.
   Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981;1(8222):681–686.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Hardinge M,
   2. Annandale J,
   3. Bourne S,
   4. Cooper B,
   5. Evans A,
   6. Freeman D,
   7. et al

   . British Thoracic Society guidelines for home oxygen use in adults. Thorax 2015;70(Suppl 1):i1–43.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   COPD Working Group. Long-term oxygen therapy for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Ont Health Technol Assess Ser 2012;12(7):1–64.

   OpenUrl
5. 5.↵
   1. Górecka D,
   2. Gorzelak K,
   3. Sliwiński P,
   4. Tobiasz M,
   5. Zieliński J

   . Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. Thorax 1997;52(8):674–679.

   OpenUrlAbstract
6. 6.
   1. Albert RK,
   2. Au DH,
   3. Blackford AL,
   4. Casaburi R,
   5. Cooper JA Jr.,
   6. et al

   Long-Term Oxygen Treatment Trial Research Group, Albert RK, Au DH, Blackford AL, Casaburi R, Cooper JA Jr., et al. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med 2016;375(17):1617–1627.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Ekström M,
   2. Ringbaek T

   . Which patients with moderate hypoxemia benefit from long-term oxygen therapy? Ways forward. Int J Chron Obstruct Pulmon Dis 2018;13:231–235.

   OpenUrl
8. 8.↵
   1. Ahmadi Z,
   2. Sundh J,
   3. Bornefalk-Hermansson A,
   4. Ekström M

   . Long-term oxygen therapy 24 vs 15 h/day and mortality in chronic obstructive pulmonary disease. PLoS One 2016;11(9):e0163293.

   OpenUrl
9. 9.↵
   1. Gulbas G,
   2. Gunen H,
   3. In E,
   4. Kilic T

   . Long-term follow-up of chronic obstructive pulmonary disease patients on long-term oxygen treatment. Int J Clin Pract 2012;66(2):152–157.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Ahmadi Z,
    2. Wysham NG,
    3. Lundström S,
    4. Janson C,
    5. Currow DC,
    6. Ekström M

    . End-of-life care in oxygen-dependent ILD compared with lung cancer: a national population-based study. Thorax 2016;71(6):510–516.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Charlson ME,
    2. Pompei P,
    3. Ales KL,
    4. MacKenzie CR

    . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40(5):373–383.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Charlson M,
    2. Szatrowski TP,
    3. Peterson J,
    4. Gold J

    . Validation of a combined comorbidity index. J Clin Epidemiol 1994;47(11):1245–1251.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    From the global strategy for the diagnosis, management and prevention of COPD, global initiative for chronic obstructive lung disease (GOLD) 2017. Available at https://goldcopd.org. Accessed March 24, 2018.
14. 14.↵
    1. Leuchte HH,
    2. Mernitz P,
    3. Baezner C,
    4. Baumgartner RA,
    5. von Wulffen W,
    6. Neurohr C,
    7. Behr J

    . Self-report daily life activity as a prognostic marker of idiopathic pulmonary fibrosis. Respiration 2015;90(6):460–467.

    OpenUrl
15. 15.↵
    1. Liu Y,
    2. Croft JB,
    3. Anderson LA,
    4. Wheaton AG,
    5. Presley-Cantrell LR,
    6. Ford ES

    . The association of chronic obstructive pulmonary disease, disability, engagement in social activities, and mortality among US adults aged 70 years or older, 1994-2006. Int J Chron Obstruct Pulmon Dis 2014;9:75–83.

    OpenUrl
16. 16.↵
    1. Stineman MG,
    2. Xie D,
    3. Pan Q,
    4. Kurichi JE,
    5. Zhang Z,
    6. Saliba D,
    7. et al

    . All-cause 1-, 5-, and 10-year mortality in elderly people according to activities of daily living stage. J Am Geriatr Soc 2012;60(3):485–492.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Okubadejo AA,
    2. O'Shea L,
    3. Jones PW,
    4. Wedzicha JA

    . Home assessment of activities of daily living in patients with severe chronic obstructive pulmonary disease on long-term oxygen therapy. Eur Respir J 1997;10(7):1572–1575.

    OpenUrlAbstract
18. 18.↵
    1. Hubbard R,
    2. Johnston I,
    3. Britton J

    . Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. Chest 1998;113(2):396–400.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.
    1. Nicholson AG,
    2. Colby TV,
    3. du Bois RM,
    4. Hansell DM,
    5. Wells AU

    . The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000;162(6):2213–2217.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.
    1. King TE Jr.,
    2. Schwarz MI,
    3. Brown K,
    4. Tooze JA,
    5. Colby TV,
    6. Waldron JA Jr.,
    7. et al

    . Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001;164(6):1025–1032.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.
    1. Mura M,
    2. Porretta MA,
    3. Bargagli E,
    4. Sergiacomi G,
    5. Zompatori M,
    6. Sverzellati N,
    7. et al

    . Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J 2012;40(1):101–109.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. King TE Jr.,
    2. Pardo A,
    3. Selman M

    . Idiopathic pulmonary fibrosis. Lancet 2011;378(9807):1949–1961.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    1. Bell EC,
    2. Cox NS,
    3. Goh N,
    4. Glaspole I,
    5. Westall GP,
    6. Watson A,
    7. Holland AE

    . Oxygen therapy for interstitial lung disease: a systematic review. Eur Respir Rev 2017;26(143). pii: 160080.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Pinto-Plata VM,
    2. Cote C,
    3. Cabral H,
    4. Taylor J,
    5. Celli BR

    . The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 2004;23(1):28–33.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    1. Puhan MA,
    2. Siebeling L,
    3. Zoller M,
    4. Muggensturm P,
    5. ter Riet G

    . Simple functional performance tests and mortality in COPD. Eur Respir J 2013;42(4):956–963.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    1. Cao C,
    2. Wang R,
    3. Wang J,
    4. Bunjhoo H,
    5. Xu Y,
    6. Xiong W

    . Body mass index and mortality in chronic obstructive pulmonary disease: a meta-analysis. PLoS One 2012;7(8):e43892.

    OpenUrlCrossRefPubMed
27. 27.
    1. Guo Y,
    2. Zhang T,
    3. Wang Z,
    4. Yu F,
    5. Xu Q,
    6. Guo W,
    7. et al

    . Body mass index and mortality in chronic obstructive pulmonary disease: a dose-response meta-analysis. Medicine (Baltimore) 2016;95(28):e4225.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Marti S,
    2. Muñoz X,
    3. Rios J,
    4. Morell F,
    5. Ferrer J

    . Body weight and comorbidity predict mortality in copd patients treated with oxygen therapy. Eur Respir J 2006;27(4):689–696.

    OpenUrlAbstract/FREE Full Text
29. 29.↵
    1. Alakhras M,
    2. Decker PA,
    3. Nadrous HF,
    4. Collazo-Clavell M,
    5. Ryu JH

    . Body mass index and mortality in patients with idiopathic pulmonary fibrosis. Chest 2007;131(5):1448–1453.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Ekström MP,
    2. Jogréus C,
    3. Ström KE

    . Comorbidity and sex-related differences in mortality in oxygen-dependent chronic obstructive pulmonary disease. PLoS One 2012;7(4):e35806.

    OpenUrlPubMed
31. 31.↵
    1. Schwarzkopf L,
    2. Witt S,
    3. Waelscher J,
    4. Polke M,
    5. Kreuter M

    . Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases - a claims data analysis. Respir Res 2018;19(1):73.

    OpenUrl
32. 32.↵
    1. Celli BR,
    2. Cote CG,
    3. Marin JM,
    4. Casanova C,
    5. Montes de Oca M,
    6. Mendez RA,
    7. et al

    . The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350(10):1005–1012.

    OpenUrlCrossRefPubMedWeb of Science
33. 33.↵
    1. Selecky PA,
    2. Eliasson CA,
    3. Hall RI,
    4. Schneider RF,
    5. Varkey B,
    6. McCaffree DR

    , American College of Chest Physicians. Palliative and end-of-life care for patients with cardiopulmonary diseases: American College of Chest Physicians Position Statement. Chest 2005;128(5):3599–3610.

    OpenUrlCrossRefPubMedWeb of Science
34. 34.↵
    1. Jabbarian LJ,
    2. Zwakman M,
    3. van der Heide A,
    4. Kars MC,
    5. Janssen DJA,
    6. van Delden JJ,
    7. et al

    . Advance care planning for patients with chronic respiratory diseases: a systematic review of preferences and practices. Thorax 2018;73(3):222–230.

    OpenUrlAbstract/FREE Full Text
35. 35.↵
    1. Rush B,
    2. Hertz P,
    3. Bond A,
    4. McDermid RC,
    5. Celi LA

    . Use of palliative care in patients with end-stage COPD and receiving home oxygen: national trends and barriers to care in the United States. Chest 2017;151(1):41–46.

    OpenUrlPubMed
36. 36.↵
    1. Kalluri M,
    2. Claveria F,
    3. Ainsley E,
    4. Haggag M,
    5. Armijo-Olivo S,
    6. Richman-Eisenstat J

    . Beyond idiopathic pulmonary fibrosis diagnosis: multidisciplinary care with an early integrated palliative approach is associated with a decrease in acute care utilization and hospital deaths. J Pain Symptom Manage 2018;55(2):420–426.

    OpenUrl
37. 37.↵
    1. Brinkman-Stoppelenburg A,
    2. Rietjens JA,
    3. van der Heide A

    . The effects of advance care planning on end-of-life care: a systematic review. Palliat Med 2014;28(8):1000–1025.

    OpenUrlCrossRefPubMed